Our top pick for
Mobile users
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy G1 Therapeutics stock | 13.19
Own G1 Therapeutics stock in just a few minutes.
G1 Therapeutics, Inc is a biotechnology business based in the US. G1 Therapeutics shares (GTHX) are listed on the NASDAQ and all prices are listed in US Dollars. G1 Therapeutics employs 104 staff and has a trailing 12-month revenue of around USD$2.1 million.
How to buy shares in G1 Therapeutics
- Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
- Search for G1 Therapeutics. Find the stock by name or ticker symbol: GTHX. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until G1 Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At last close price of USD$13.19, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of G1 Therapeutics, depending on your broker.
- Check in on your investment. Congratulations, you own a part of G1 Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
How has coronavirus impacted G1 Therapeutics's share price?
Since the stock market crash in March caused by coronavirus, G1 Therapeutics's share price has had significant negative movement.
Its last market close was USD$13.19, which is 26.56% down on its pre-crash value of USD$17.96 and 49.89% up on the lowest point reached during the March crash when the shares fell as low as USD$8.8.
If you had bought USD$1,000 worth of G1 Therapeutics shares at the start of February 2020, those shares would have been worth USD$527.95 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$652.64.
G1 Therapeutics share price
Use our graph to track the performance of GTHX stocks over time.G1 Therapeutics shares at a glance
Information last updated 2020-10-20.
| Latest market close | USD$13.19 |
|---|---|
| 52-week range | USD$8.8 - USD$31.38 |
| 50-day moving average | USD$13.8937 |
| 200-day moving average | USD$16.2641 |
| Wall St. target price | USD$56.86 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | USD$-2.703 |
Buy G1 Therapeutics shares from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy G1 Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
G1 Therapeutics price performance over time
Historical closes compared with the close of $13.19 from 2020-11-16
| 1 week (2020-11-20) | 4.60% |
|---|---|
| 1 month (2020-10-30) | 20.02% |
| 3 months (2020-08-28) | -13.51% |
| 6 months (2020-05-29) | -22.27% |
| 1 year (2019-11-29) | -38.94% |
|---|---|
| 2 years (2018-11-29) | -66.54% |
| 3 years (2017-11-29) | -37.49% |
| 5 years (2015-11-26) | N/A |
G1 Therapeutics financials
| Revenue TTM | USD$2.1 million |
|---|---|
| Gross profit TTM | USD$0 |
| Return on assets TTM | -28.45% |
| Return on equity TTM | -50.35% |
| Profit margin | 0% |
| Book value | $5.377 |
| Market capitalisation | USD$499.1 million |
TTM: trailing 12 months
Shorting G1 Therapeutics shares
There are currently 6.9 million G1 Therapeutics shares held short by investors – that's known as G1 Therapeutics's "short interest". This figure is 39.6% up from 4.9 million last month.
There are a few different ways that this level of interest in shorting G1 Therapeutics shares can be evaluated.
G1 Therapeutics's "short interest ratio" (SIR)
G1 Therapeutics's "short interest ratio" (SIR) is the quantity of G1 Therapeutics shares currently shorted divided by the average quantity of G1 Therapeutics shares traded daily (recently around 810080.61465721). G1 Therapeutics's SIR currently stands at 8.46. In other words for every 100,000 G1 Therapeutics shares traded daily on the market, roughly 8460 shares are currently held short.
However G1 Therapeutics's short interest can also be evaluated against the total number of G1 Therapeutics shares, or, against the total number of tradable G1 Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case G1 Therapeutics's short interest could be expressed as 0.18% of the outstanding shares (for every 100,000 G1 Therapeutics shares in existence, roughly 180 shares are currently held short) or 0.2946% of the tradable shares (for every 100,000 tradable G1 Therapeutics shares, roughly 295 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against G1 Therapeutics.
Find out more about how you can short G1 Therapeutics stock.
G1 Therapeutics share dividends
We're not expecting G1 Therapeutics to pay a dividend over the next 12 months.
G1 Therapeutics share price volatility
Over the last 12 months, G1 Therapeutics's shares have ranged in value from as little as $8.8 up to $31.38. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while G1 Therapeutics's is 2.0521. This would suggest that G1 Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
G1 Therapeutics overview
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2 clinical trials for patients with extensive-stage small cell lung cancer(SCLC), as well as Phase 2 clinical trial for patients with first-line (SCLC) and metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase 1b/2a clinical trials for the treatment of breast cancer and in Phase 1b clinical trial for non-small cell lung cancer; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase I/2 clinical trial. G1 Therapeutics, Inc. has a collaboration with Quantum Leap Healthcare Collaborative to evaluate trilaciclib for neoadjuvant treatment of locally advanced breast cancer. The company was founded in 2008 and is headquartered in Research Triangle Park, North Carolina.
Frequently asked questions
More guides on Finder
-
How to buy Chase Corporation stock
Steps to owning and managing CCF, with 24-hour and historical pricing before you buy.
-
How to buy CDW Corporation stock | 139.08
Steps to owning and managing CDW, with 24-hour and historical pricing before you buy.
-
How to buy Camping World stock
Steps to owning and managing CWH, with 24-hour and historical pricing before you buy.
-
How to buy Catalyst Biosciences stock
Steps to owning and managing CBIO, with 24-hour and historical pricing before you buy.
-
How to buy Bridgeline Digital stock
Steps to owning and managing BLIN, with 24-hour and historical pricing before you buy.
-
How to buy Calavo Growers stock | 72.77
Steps to owning and managing CVGW, with 24-hour and historical pricing before you buy.
-
How to buy Aegion Corporation stock | 15.82
Steps to owning and managing AEGN, with 24-hour and historical pricing before you buy.
-
How to buy Arthur JGallagher-and-Co stock
Steps to owning and managing AJG, with 24-hour and historical pricing before you buy.
-
How to buy ABB stock
Steps to owning and managing ABB, with 24-hour and historical pricing before you buy.
-
How to buy Youngevity International stock
Steps to owning and managing YGYI, with 24-hour and historical pricing before you buy.
Ask an Expert